Company Profile:

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Recent News:

The company will report its first quarter of fiscal year 2018 results on Thursday, October 26, 2017, after the New York Stock Exchange market closes. A press release with ResMed’s results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook.

For the quarter ended June 30, 2017, the company reported Revenues of USD 556.69 million, increased 7.3% year over year. Including one-time items, ResMed reported EPS of $0.71 in the quarter, up 20.4% year over year.

Also, ResMed announced an increase in quarterly dividend by 6% to 35 cents per share. The dividend will be paid out on on Sep 21, 2017, to shareholders on record as of Aug 17, 2017.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

RMD’s strengths can be seen in its strong profitability and better efficiency compared with its peers. It revenue has increased over several years. Technical indicators signal the bullish signs, as there is a bullish cross in Stochastic Oscillator, RSI (14) stands at 53.28 with positive bias. We rate ResMed Inc. (RMD) a STRONG BUY.